Champions Oncology, Inc. (CSBR): Total Assets
$26.99M
As of 2026-04-30
$33.29M
As of 2026-07-31
-7.7%
3-year compound annual growth
-0.4%
5-year compound annual growth
+16.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $26.99M | -16.6% | 2026-07-27, Balance as of period end |
| 2025-04-30 | $32.34M | +23.8% | 2026-07-27, Balance as of period end |
| 2024-04-30 | $26.13M | -23.8% | 2025-07-23, Balance as of period end |
| 2023-04-30 | $34.31M | -3.0% | 2024-07-19, Balance as of period end |
| 2022-04-30 | $35.38M | +28.2% | 2023-07-24, Balance as of period end |
| 2021-04-30 | $27.59M | +33.0% | 2022-07-22, Balance as of period end |
| 2020-04-30 | $20.75M | +84.2% | 2021-07-26, Balance as of period end |
| 2019-04-30 | $11.27M | +39.5% | 2020-07-28, Balance as of period end |
| 2018-04-30 | $8.08M | +0.8% | 2019-07-29, Balance as of period end |
| 2017-04-30 | $8.01M | +38.7% | 2018-07-30, Balance as of period end |
| 2016-04-30 | $5.78M | -52.0% | 2017-07-28, Balance as of period end |
| 2015-04-30 | $12.05M | +35.9% | 2016-07-29, Balance as of period end |
| 2014-04-30 | $8.87M | -23.9% | 2015-07-29, Balance as of period end |
| 2013-04-30 | $11.65M | +68.3% | 2014-07-28, Balance as of period end |
| 2012-04-30 | $6.92M | -45.3% | 2013-07-26, Balance as of period end |
| 2011-04-30 | $12.65M | n/a | 2012-07-18, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $82.35M | +12.2% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.47B | +1.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $589.07M | -24.7% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
Compare CSBR, IVVD, PLX, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗